Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001607062-23-000215
Filing Date
2023-04-18
Accepted
2023-04-18 10:44:19
Documents
50
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rgbp033123form10q.htm   iXBRL 10-Q 737268
2 EXHIBIT 31.1 ex31_1.htm EX-31.1 9481
3 EXHIBIT 31.2 ex31_2.htm EX-31.2 9481
4 EXHIBIT 32.1 ex32_1.htm EX-32.1 4221
5 EXHIBIT 32.2 ex32_2.htm EX-32.2 4098
  Complete submission text file 0001607062-23-000215.txt   3695643

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE rgbp-20230331.xsd EX-101.SCH 48419
7 XBRL CALCULATION FILE rgbp-20230331_cal.xml EX-101.CAL 49191
8 XBRL DEFINITION FILE rgbp-20230331_def.xml EX-101.DEF 140007
9 XBRL LABEL FILE rgbp-20230331_lab.xml EX-101.LAB 263243
10 XBRL PRESENTATION FILE rgbp-20230331_pre.xml EX-101.PRE 207789
44 EXTRACTED XBRL INSTANCE DOCUMENT rgbp033123form10q_htm.xml XML 428409
Mailing Address 4700 SPRING ST #304 LA MESA CA 91942
Business Address 4700 SPRING ST #304 LA MESA CA 91942 619-722-5505
Regen BioPharma Inc (Filer) CIK: 0001589150 (see all company filings)

EIN.: 455192997 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 333-191725 | Film No.: 23825830
SIC: 2834 Pharmaceutical Preparations